Oncolytics Biotech Inc. (ONCY)
USD 0.55
(0.0%)
USD 0.55
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 290 Thousand CAD | 84.71% |
| 2022 | 157 Thousand CAD | -56.52% |
| 2021 | 361.08 Thousand CAD | 135.73% |
| 2020 | 153.17 Thousand CAD | -7.96% |
| 2019 | 166.42 Thousand CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | -100.0% |
| 2006 | 150 Thousand CAD | 0.0% |
| 2005 | 150 Thousand CAD | 0.0% |
| 2004 | 150 Thousand CAD | 0.0% |
| 2003 | 150 Thousand CAD | 0.0% |
| 2002 | 150 Thousand CAD | 0.0% |
| 2001 | 150 Thousand CAD | 0.0% |
| 2000 | 150 Thousand CAD | 0.0% |
| 1999 | 150 Thousand CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 891 Thousand CAD | 0.0% |
| 2024 Q1 | 948 Thousand CAD | 0.0% |
| 2023 Q2 | 346 Thousand CAD | -8.47% |
| 2023 Q1 | 378 Thousand USD | 140.76% |
| 2023 FY | 290 Thousand CAD | 84.71% |
| 2023 Q3 | 323 Thousand CAD | -6.65% |
| 2023 Q4 | 290 Thousand CAD | -10.22% |
| 2022 FY | 157 Thousand CAD | -56.52% |
| 2022 Q2 | 192.09 Thousand CAD | -30.56% |
| 2022 Q4 | 157 Thousand CAD | -5.37% |
| 2022 Q3 | 165.91 Thousand CAD | -13.63% |
| 2022 Q1 | 276.64 Thousand CAD | -23.39% |
| 2021 FY | 361.08 Thousand CAD | 135.73% |
| 2021 Q3 | 441.98 Thousand CAD | -13.4% |
| 2021 Q1 | 371.97 Thousand CAD | 142.84% |
| 2021 Q4 | 361.08 Thousand CAD | -18.3% |
| 2021 Q2 | 510.36 Thousand CAD | 37.21% |
| 2020 Q2 | 17.39 Thousand CAD | -81.36% |
| 2020 FY | 153.17 Thousand CAD | -7.96% |
| 2020 Q4 | 153.17 Thousand CAD | -16.8% |
| 2020 Q1 | 93.35 Thousand CAD | -43.91% |
| 2020 Q3 | 184.1 Thousand CAD | 958.15% |
| 2019 Q2 | 316.85 Thousand CAD | -24.6% |
| 2019 Q4 | 166.42 Thousand CAD | -32.26% |
| 2019 Q3 | 245.7 Thousand CAD | -22.46% |
| 2019 FY | 166.42 Thousand CAD | 0.0% |
| 2019 Q1 | 420.22 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | -100.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q1 | - CAD | -100.0% |
| 2006 FY | 150 Thousand CAD | 0.0% |
| 2006 Q2 | 150 Thousand CAD | 0.0% |
| 2006 Q3 | 150 Thousand CAD | 0.0% |
| 2006 Q4 | 150 Thousand CAD | 0.0% |
| 2006 Q1 | 150 Thousand CAD | 0.0% |
| 2005 Q4 | 150 Thousand CAD | -13.9% |
| 2005 Q1 | 150 Thousand CAD | 0.0% |
| 2005 Q2 | 150 Thousand CAD | 0.0% |
| 2005 Q3 | 174.21 Thousand CAD | 16.14% |
| 2005 FY | 150 Thousand CAD | 0.0% |
| 2004 Q4 | 150 Thousand CAD | 0.0% |
| 2004 Q2 | 150 Thousand CAD | 0.0% |
| 2004 Q3 | 150 Thousand CAD | 0.0% |
| 2004 FY | 150 Thousand CAD | 0.0% |
| 2004 Q1 | 150 Thousand CAD | 0.0% |
| 2003 Q4 | 150 Thousand CAD | 0.0% |
| 2003 FY | 150 Thousand CAD | 0.0% |
| 2003 Q1 | 150 Thousand CAD | 0.0% |
| 2003 Q2 | 150 Thousand CAD | 0.0% |
| 2003 Q3 | 150 Thousand CAD | 0.0% |
| 2002 Q1 | 150 Thousand CAD | 0.0% |
| 2002 Q2 | 150 Thousand CAD | 0.0% |
| 2002 Q3 | 161.9 Thousand CAD | 7.94% |
| 2002 FY | 150 Thousand CAD | 0.0% |
| 2002 Q4 | 150 Thousand CAD | -7.35% |
| 2001 Q1 | - CAD | -100.0% |
| 2001 Q4 | 150 Thousand CAD | 0.0% |
| 2001 Q3 | 150 Thousand CAD | 0.0% |
| 2001 FY | 150 Thousand CAD | 0.0% |
| 2001 Q2 | 150 Thousand CAD | 0.0% |
| 2000 Q4 | 150 Thousand CAD | 0.0% |
| 2000 Q3 | 150 Thousand CAD | 0.0% |
| 2000 Q2 | 150 Thousand CAD | 0.0% |
| 2000 Q1 | 150 Thousand CAD | 0.0% |
| 2000 FY | 150 Thousand CAD | 0.0% |
| 1999 FY | 150 Thousand CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Absci Corporation | 4.66 Million USD | 93.777% |
| Adaptive Biotechnologies Corporation | 130.66 Million USD | 99.778% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.988% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Apollomics, Inc. | 267 Thousand USD | -8.614% |
| 180 Life Sciences Corp. | 19.93 Thousand USD | -1354.655% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Bicycle Therapeutics plc | 40.08 Million USD | 99.276% |
| Barinthus Biotherapeutics plc | 11.19 Million USD | 97.409% |
| BioXcel Therapeutics, Inc. | 100.59 Million USD | 99.712% |
| CASI Pharmaceuticals, Inc. | 18.89 Million USD | 98.465% |
| Chimerix, Inc. | 125 Thousand USD | -132.0% |
| CRISPR Therapeutics AG | 223 Million USD | 99.87% |
| Contineum Therapeutics, Inc. Class A Common Stock | 192.62 Million USD | 99.849% |
| EyePoint Pharmaceuticals, Inc. | 4.9 Million USD | 94.089% |
| Fortress Biotech, Inc. | 60.85 Million USD | 99.523% |
| Fortress Biotech, Inc. | 60.85 Million USD | 99.523% |
| Gritstone bio, Inc. | 40.14 Million USD | 99.278% |
| Allakos Inc. | 38.21 Million USD | 99.241% |
| Boundless Bio, Inc. Common Stock | 247.61 Million USD | 99.883% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 99.218% |
| Cytokinetics, Incorporated | 607.37 Million USD | 99.952% |
| enGene Holdings Inc. Common Stock | 9.21 Million USD | 96.853% |
| Innoviva, Inc. | 446.23 Million USD | 99.935% |
| Hoth Therapeutics, Inc. | 26.32 Thousand USD | -1001.573% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | 4.45 Million USD | 93.495% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| Vigil Neuroscience, Inc. | 12.94 Million USD | 97.76% |
| ImmuCell Corporation | 10.54 Million USD | 97.249% |
| IDEAYA Biosciences, Inc. | 1.12 Million USD | 74.222% |
| Incyte Corporation | 29.16 Million USD | 99.006% |
| Inovio Pharmaceuticals, Inc. | 11.03 Million USD | 97.371% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -112.964% |
| Mustang Bio, Inc. | 1.97 Million USD | 85.339% |
| MiMedx Group, Inc. | 48.09 Million USD | 99.397% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| MacroGenics, Inc. | 30.19 Million USD | 99.04% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Mereo BioPharma Group plc | 5.3 Million USD | 94.528% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 95.18 Million USD | 99.695% |
| Maravai LifeSciences Holdings, Inc. | 518.7 Million USD | 99.944% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 99.646% |
| NeuroBo Pharmaceuticals, Inc. | 136 Thousand USD | -113.235% |
| NeuroSense Therapeutics Ltd. | 73 Thousand USD | -297.26% |
| NextCure, Inc. | 5.94 Million USD | 95.125% |
| Orchestra BioMed Holdings, Inc. | 1.03 Million USD | 72.062% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 118.85 Thousand USD | -143.991% |
| Oncternal Therapeutics, Inc. | 145 Thousand USD | -100.0% |
| Opthea Limited | 200.53 Million USD | 99.855% |
| Ovid Therapeutics Inc. | 30 Million USD | 99.033% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| PDS Biotechnology Corporation | 19.5 Million USD | 98.513% |
| Precigen, Inc. | 5.89 Million USD | 95.081% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Prime Medicine, Inc. | 4.35 Million USD | 93.344% |
| PureTech Health plc | 18.25 Million USD | 98.411% |
| Rocket Pharmaceuticals, Inc. | 22.32 Million USD | 98.701% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.989% |
| Replimune Group, Inc. | 71.99 Million USD | 99.597% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Rigel Pharmaceuticals, Inc. | 52.65 Million USD | 99.449% |
| TransCode Therapeutics, Inc. | 38.29 Thousand USD | -657.358% |
| Revolution Medicines, Inc. Warrant | 80.57 Million USD | 99.64% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 99.135% |
| Solid Biosciences Inc. | 23.94 Million USD | 98.789% |
| Syndax Pharmaceuticals, Inc. | 588 Thousand USD | 50.68% |
| SciSparc Ltd. | 24 Thousand USD | -1108.333% |
| Sutro Biopharma, Inc. | 149.11 Million USD | 99.806% |
| TG Therapeutics, Inc. | 100.11 Million USD | 99.71% |
| Tonix Pharmaceuticals Holding Corp. | 6.56 Million USD | 95.58% |
| Titan Pharmaceuticals, Inc. | - USD | -Infinity% |
| Travere Therapeutics, Inc. | 377.26 Million USD | 99.923% |
| UroGen Pharma Ltd. | 98.55 Million USD | 99.706% |
| Verrica Pharmaceuticals Inc. | 42.87 Million USD | 99.324% |
| XOMA Corporation | 118.51 Million USD | 99.755% |
| Zentalis Pharmaceuticals, Inc. | 43.15 Million USD | 99.328% |
| AbCellera Biologics Inc. | 71.22 Million USD | 99.593% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 91.046% |
| Precision BioSciences, Inc. | 7.72 Million USD | 96.245% |
| Dyadic International, Inc. | 88.87 Thousand USD | -226.319% |
| Intensity Therapeutics, Inc. | 138 Thousand USD | -110.145% |
| Eton Pharmaceuticals, Inc. | 22 Thousand USD | -1218.182% |
| VYNE Therapeutics Inc. | 99 Thousand USD | -192.929% |
| Tenaya Therapeutics, Inc. | 8.1 Million USD | 96.422% |
| IGM Biosciences, Inc. | 34.67 Million USD | 99.164% |
| X4 Pharmaceuticals, Inc. | 54.57 Million USD | 99.469% |
| Acelyrin, Inc. | 1.19 Million USD | 75.712% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 93.412% |
| Ligand Pharmaceuticals Incorporated | 5.75 Million USD | 94.961% |
| Inhibikase Therapeutics, Inc. | 90.12 Thousand USD | -221.779% |
| Arcturus Therapeutics Holdings Inc. | 25.9 Million USD | 98.881% |
| Syros Pharmaceuticals, Inc. | 34.55 Million USD | 99.161% |
| Senti Biosciences, Inc. | 33.53 Million USD | 99.135% |
| Mesoblast Limited | 100.48 Million USD | 99.711% |
| Kymera Therapeutics, Inc. | 78.32 Million USD | 99.63% |
| ChromaDex Corporation | 2.57 Million USD | 88.738% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 71.19 Million USD | 99.593% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 25.96 Million USD | 98.883% |
| Xeris Biopharma Holdings, Inc. | 190.93 Million USD | 99.848% |
| Novavax, Inc. | 168.01 Million USD | 99.827% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Fate Therapeutics, Inc. | 97.36 Million USD | 99.702% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Lyell Immunopharma, Inc. | 56.89 Million USD | 99.49% |
| Celcuity Inc. | 37.03 Million USD | 99.217% |
| ContextLogic Inc. | 6 Million USD | 95.167% |
| Phathom Pharmaceuticals, Inc. | 138.3 Million USD | 99.79% |
| HOOKIPA Pharma Inc. | 3.8 Million USD | 92.37% |
| Jazz Pharmaceuticals plc | 5.1 Billion USD | 99.994% |
| Amarin Corporation plc | 8.73 Million USD | 96.681% |
| AnaptysBio, Inc. | 16.03 Million USD | 98.192% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | 94.627% |
| Aptorum Group Limited | 3.05 Million USD | 90.518% |
| Cartesian Therapeutics, Inc. | 8.78 Million USD | 96.7% |
| Arrowhead Pharmaceuticals, Inc. | 104.6 Million USD | 99.723% |
| Ardelyx, Inc. | 51.54 Million USD | 99.437% |
| Celularity Inc. | 26.17 Million USD | 98.892% |
| Omeros Corporation | 329.7 Million USD | 99.912% |
| Humacyte, Inc. | 38.6 Million USD | 99.249% |
| Immunocore Holdings plc | 82.64 Million USD | 99.649% |
| IO Biotech, Inc. | 1.83 Million USD | 84.231% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | 1.45 Million USD | 80.11% |
| Summit Therapeutics Inc. | 103.29 Million USD | 99.719% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Pulmatrix, Inc. | 8.32 Million USD | 96.517% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 99.7% |
| Evogene Ltd. | 10.65 Million USD | 97.278% |
| CorMedix Inc. | 517.01 Thousand USD | 43.909% |
| BioLineRx Ltd. | 6.62 Million USD | 95.625% |
| VistaGen Therapeutics, Inc. | 1.57 Million USD | 81.529% |
| Sagimet Biosciences Inc. | - USD | -Infinity% |
| PTC Therapeutics, Inc. | 284.21 Million USD | 99.898% |
| scPharmaceuticals Inc. | 38.81 Million USD | 99.253% |
| Fulcrum Therapeutics, Inc. | 8.62 Million USD | 96.639% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Akero Therapeutics, Inc. | 24.96 Million USD | 98.838% |
| Eliem Therapeutics, Inc. | 15 Thousand USD | -1833.333% |
| Lisata Therapeutics, Inc. | 137.00 USD | -211578.832% |
| Stoke Therapeutics, Inc. | 4.77 Million USD | 93.924% |
| Reneo Pharmaceuticals, Inc. | 642 Thousand USD | 54.829% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| Daré Bioscience, Inc. | 3.91 Million USD | 92.59% |
| bluebird bio, Inc. | 224.41 Million USD | 99.871% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.951% |
| DBV Technologies S.A. | 4.52 Million USD | 93.593% |
| Avidity Biosciences, Inc. | 6.21 Million USD | 95.332% |
| Galecto, Inc. | 66 Thousand USD | -339.394% |
| Sensei Biotherapeutics, Inc. | 3.76 Million USD | 92.306% |
| Spruce Biosciences, Inc. | 1.71 Million USD | 83.11% |
| Inhibrx Biosciences, Inc. | 206.96 Million USD | 99.86% |
| GlycoMimetics, Inc. | 66.84 Thousand USD | -333.846% |
| Arcutis Biotherapeutics, Inc. | 201.79 Million USD | 99.856% |
| ADMA Biologics, Inc. | 130.59 Million USD | 99.778% |
| Clene Inc. | 7.15 Million USD | 95.945% |
| Recursion Pharmaceuticals, Inc. | 1.1 Million USD | 73.66% |
| Aptose Biosciences Inc. | 621 Thousand USD | 53.301% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 1.01 Million USD | 71.314% |
| Century Therapeutics, Inc. | 46.65 Million USD | 99.378% |
| Kura Oncology, Inc. | 9.33 Million USD | 96.892% |
| Surrozen, Inc. | 882 Thousand USD | 67.12% |
| TScan Therapeutics, Inc. | 26.7 Million USD | 98.914% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 9.38 Million USD | 96.91% |
| Autolus Therapeutics plc | 47.91 Million USD | 99.395% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Eterna Therapeutics Inc. | 6.77 Million USD | 95.718% |
| Caribou Biosciences, Inc. | 25.9 Million USD | 98.881% |
| GRI Bio, Inc. | - USD | -Infinity% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Janux Therapeutics, Inc. | 23.02 Million USD | 98.74% |
| INmune Bio, Inc. | 397 Thousand USD | 26.952% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.833% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 92.847% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Jaguar Health, Inc. | 30.99 Million USD | 99.064% |
| Entero Therapeutics, Inc. | 146.94 Thousand USD | -97.347% |
| Milestone Pharmaceuticals Inc. | 49.77 Million USD | 99.417% |
| Clearside Biomedical, Inc. | 41.98 Million USD | 99.309% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 99.365% |
| Coherus BioSciences, Inc. | 473.36 Million USD | 99.939% |
| Verastem, Inc. | 40.08 Million USD | 99.277% |
| Pliant Therapeutics, Inc. | 10.05 Million USD | 97.116% |
| Histogen Inc. | 4.38 Million USD | 93.385% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 47.8 Million USD | 99.393% |
| Surrozen, Inc. | 882 Thousand USD | 67.12% |
| Organovo Holdings, Inc. | 888 Thousand USD | 67.342% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 75.7 Million USD | 99.617% |
| Hepion Pharmaceuticals, Inc. | 93.1 Thousand USD | -211.48% |
| BioRestorative Therapies, Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 25.37 Million USD | 98.857% |
| Turnstone Biologics Corp. | 1.18 Million USD | 75.61% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 109 Thousand USD | -166.055% |
| Entrada Therapeutics, Inc. | 60.32 Million USD | 99.519% |
| Aurinia Pharmaceuticals Inc. | 82 Million USD | 99.646% |
| Exelixis, Inc. | 189.94 Million USD | 99.847% |
| Nurix Therapeutics, Inc. | 23.12 Million USD | 98.746% |
| Apellis Pharmaceuticals, Inc. | 93.03 Million USD | 99.688% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 84.013% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 153.59 Million USD | 99.811% |
| Insmed Incorporated | 1.19 Billion USD | 99.976% |
| MediWound Ltd. | 6.35 Million USD | 95.433% |
| OmniAb, Inc. | 22.07 Million USD | 98.686% |
| Alector, Inc. | 30.45 Million USD | 99.048% |
| Seres Therapeutics, Inc. | 101.54 Million USD | 99.714% |
| Zai Lab Limited | 8.04 Million USD | 96.396% |
| AlloVir, Inc. | 16.64 Million USD | 98.258% |
| Revance Therapeutics, Inc. | 426.59 Million USD | 99.932% |
| ORIC Pharmaceuticals, Inc. | 7461.00 USD | -3786.878% |
| Aura Biosciences, Inc. | 16.87 Million USD | 98.281% |
| Immunic, Inc. | 639 Thousand USD | 54.617% |
| Tarsus Pharmaceuticals, Inc. | 29.81 Million USD | 99.027% |
| Veracyte, Inc. | 7.52 Million USD | 96.146% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.955% |
| FibroGen, Inc. | 89.69 Million USD | 99.677% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 93.313% |
| Catalyst Pharmaceuticals, Inc. | 3.18 Million USD | 90.903% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 130.86 Thousand USD | -121.606% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -683.784% |
| Amylyx Pharmaceuticals, Inc. | 1.98 Million USD | 85.354% |
| Fortrea Holdings Inc. | 1.63 Billion USD | 99.982% |
| KalVista Pharmaceuticals, Inc. | 6.01 Million USD | 95.179% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 84.013% |
| Keros Therapeutics, Inc. | 13.43 Million USD | 97.842% |
| SELLAS Life Sciences Group, Inc. | 460 Thousand USD | 36.957% |
| Lyra Therapeutics, Inc. | 21.44 Million USD | 98.648% |
| Foghorn Therapeutics Inc. | 36.55 Million USD | 99.207% |
| Agenus Inc. | 137.32 Million USD | 99.789% |
| Y-mAbs Therapeutics, Inc. | 517 Thousand USD | 43.907% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 99.359% |
| Ultragenyx Pharmaceutical Inc. | 30.57 Million USD | 99.051% |
| Metagenomi, Inc. Common Stock | 44.8 Million USD | 99.353% |
| BioCryst Pharmaceuticals, Inc. | 811.26 Million USD | 99.964% |
| Gain Therapeutics, Inc. | 449.05 Thousand USD | 35.42% |
| C4 Therapeutics, Inc. | 65.75 Million USD | 99.559% |
| Creative Medical Technology Holdings, Inc. | - USD | -Infinity% |
| Chemomab Therapeutics Ltd. | 316 Thousand USD | 8.228% |
| Lantern Pharma Inc. | 61.49 Thousand USD | -371.575% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ainos, Inc. | 5.92 Million USD | 95.103% |
| Pluri Inc. | 29.05 Million USD | 99.002% |
| Prothena Corporation plc | 10.72 Million USD | 97.295% |
| Adaptimmune Therapeutics plc | 19.85 Million USD | 98.539% |
| Rallybio Corporation | 173 Thousand USD | -67.63% |
| Kodiak Sciences Inc. | 100 Million USD | 99.71% |
| Cue Biopharma, Inc. | 4.2 Million USD | 93.099% |
| MeiraGTx Holdings plc | 72.11 Million USD | 99.598% |
| Annexon, Inc. | 29.19 Million USD | 99.007% |
| Assembly Biosciences, Inc. | 1.12 Million USD | 74.153% |
| Moderna, Inc. | - USD | -Infinity% |
| Cocrystal Pharma, Inc. | 1.61 Million USD | 82.021% |
| Cidara Therapeutics, Inc. | 3.57 Million USD | 91.893% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.953% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Monte Rosa Therapeutics, Inc. | 42.87 Million USD | 99.324% |
| Scholar Rock Holding Corporation | 48.68 Million USD | 99.404% |
| Wave Life Sciences Ltd. | 25.4 Million USD | 98.858% |
| Sana Biotechnology, Inc. | 90.9 Million USD | 99.681% |
| Elicio Therapeutics, Inc. | 6 Million USD | 95.172% |
| Adlai Nortye Ltd. American Depositary Shares | 469 Thousand USD | 38.166% |
| Nutriband Inc. | 79.82 Thousand USD | -263.29% |
| Protara Therapeutics, Inc. | 4.48 Million USD | 93.533% |
| Vor Biopharma Inc. | 31.83 Million USD | 99.089% |
| Roivant Sciences Ltd. | 477.85 Million USD | 99.939% |
| Alkermes plc | 287.73 Million USD | 99.899% |
| ProKidney Corp. | 3.61 Million USD | 91.967% |
| Applied Therapeutics, Inc. | 759 Thousand USD | 61.792% |
| Arcellx, Inc. | 50.84 Million USD | 99.43% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.983% |
| Tango Therapeutics, Inc. | 36.83 Million USD | 99.213% |
| Galectin Therapeutics Inc. | 71.74 Million USD | 99.596% |
| Atai Life Sciences N.V. | 15.21 Million USD | 98.093% |
| Renovaro Biosciences Inc. | 842.38 Thousand USD | 65.574% |
| Aerovate Therapeutics, Inc. | 255 Thousand USD | -13.725% |
| MediciNova, Inc. | 410.66 Thousand USD | 29.382% |
| Praxis Precision Medicines, Inc. | 1.36 Million USD | 78.817% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 56.266% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 99.837% |
| Biomea Fusion, Inc. | 7.83 Million USD | 96.296% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Cullinan Oncology, Inc. | 2.15 Million USD | 86.512% |
| Geron Corporation | 35.05 Million USD | 99.173% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 11.52 Million USD | 97.483% |
| Dyne Therapeutics, Inc. | 22.69 Million USD | 98.722% |
| Kiniksa Pharmaceuticals, Ltd. | 10 Million USD | 97.101% |
| Royalty Pharma plc | 6.13 Billion USD | 99.995% |
| Ventyx Biosciences, Inc. | 11.5 Million USD | 97.479% |
| Imunon, Inc. | 1.13 Million USD | 74.546% |
| BioAtla, Inc. | 836 Thousand USD | 65.311% |
| Allogene Therapeutics, Inc. | 88.34 Million USD | 99.672% |
| Larimar Therapeutics, Inc. | 4.7 Million USD | 93.842% |
| Mersana Therapeutics, Inc. | 23.14 Million USD | 98.747% |
| Structure Therapeutics Inc. | 4.01 Million USD | 92.773% |
| 89bio, Inc. | 24.79 Million USD | 98.83% |
| Kezar Life Sciences, Inc. | 10.06 Million USD | 97.12% |
| aTyr Pharma, Inc. | 13.76 Million USD | 97.894% |
| Aligos Therapeutics, Inc. | 7.89 Million USD | 96.329% |
| Viridian Therapeutics, Inc. | 20.2 Million USD | 98.565% |
| EyeGate Pharmaceuticals, Inc. | 278.19 Thousand USD | -4.245% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 97.994% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.981% |
| Lexicon Pharmaceuticals, Inc. | 99.5 Million USD | 99.709% |
| Liquidia Corporation | 2.36 Million USD | 87.733% |
| Entera Bio Ltd. | 256 Thousand USD | -13.281% |
| GH Research PLC | 631 Thousand USD | 54.041% |
| Vericel Corporation | 81.85 Million USD | 99.646% |
| Arbutus Biopharma Corporation | 6.95 Million USD | 95.829% |
| Xencor, Inc. | 14.64 Million USD | 98.019% |
| 60 Degrees Pharmaceuticals, Inc. | 150.25 Thousand USD | -93.01% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Coeptis Therapeutics Holdings, Inc. | 150 Thousand USD | -93.333% |
| Vaxcyte, Inc. | 22.11 Million USD | 98.688% |
| Xenon Pharmaceuticals Inc. | 9.6 Million USD | 96.98% |
| Vanda Pharmaceuticals Inc. | 7 Million USD | 95.861% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -112.964% |
| Portage Biotech Inc. | 7000.00 USD | -4042.857% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 56.266% |
| Olema Pharmaceuticals, Inc. | 1.42 Million USD | 79.706% |
| OncoCyte Corporation | 2.2 Million USD | 86.842% |
| Qualigen Therapeutics, Inc. | - USD | -Infinity% |
| Processa Pharmaceuticals, Inc. | 66.9 Thousand USD | -333.45% |
| Purple Biotech Ltd. | 163 Thousand USD | -77.914% |
| Tempest Therapeutics, Inc. | 6.26 Million USD | 95.37% |
| Sol-Gel Technologies Ltd. | 1.2 Million USD | 75.954% |
| Rhythm Pharmaceuticals, Inc. | 490 Thousand USD | 40.816% |
| CollPlant Biotechnologies Ltd. | 2.53 Million USD | 88.56% |
| Moleculin Biotech, Inc. | 474 Thousand USD | 38.819% |
| United Therapeutics Corporation | 300 Million USD | 99.903% |
| HilleVax, Inc. | 25.24 Million USD | 98.851% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 99.825% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | 933 Thousand USD | 68.917% |
| Neumora Therapeutics, Inc. Common Stock | 1.85 Million USD | 84.35% |
| Pyxis Oncology, Inc. | 20.09 Million USD | 98.557% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.34 Million USD | 98.899% |
| Windtree Therapeutics, Inc. | 15 Million USD | 98.067% |
| Curis, Inc. | 1.48 Million USD | 80.524% |
| Carmell Therapeutics Corporation | 697.71 Thousand USD | 58.436% |
| Achieve Life Sciences, Inc. | 6000.00 USD | -4733.333% |
| BeiGene, Ltd. | 197.61 Million USD | 99.853% |
| Protagonist Therapeutics, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 51.88 Million USD | 99.441% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 1.34 Million USD | 78.358% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Acrivon Therapeutics, Inc. Common Stock | 3.76 Million USD | 92.302% |
| Celldex Therapeutics, Inc. | 928 Thousand USD | 68.75% |
| Cogent Biosciences, Inc. | 17.46 Million USD | 98.34% |
| Adicet Bio, Inc. | 17.7 Million USD | 98.362% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.925% |
| Aditxt, Inc. | 1.04 Million USD | 72.162% |
| Adagene Inc. | 13.54 Million USD | 97.858% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 97.889% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 17.09 Million USD | 98.303% |
| Compugen Ltd. | 719 Thousand USD | 59.666% |
| Generation Bio Co. | 89.77 Million USD | 99.677% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | 22.18 Million USD | 98.693% |
| Invivyd, Inc. | 722 Thousand USD | 59.834% |
| Relay Therapeutics, Inc. | 48.5 Million USD | 99.402% |
| Quoin Pharmaceuticals, Ltd. | 2923.73 USD | -9818.837% |
| Spero Therapeutics, Inc. | 3.82 Million USD | 92.418% |
| Artelo Biosciences, Inc. | 23 Thousand USD | -1160.87% |
| 2seventy bio, Inc. | 244.01 Million USD | 99.881% |
| Instil Bio, Inc. | 81.42 Million USD | 99.644% |
| Capricor Therapeutics, Inc. | 3.37 Million USD | 91.411% |
| Elevai Labs, Inc. Common Stock | 65.48 Thousand USD | -342.822% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Citius Pharmaceuticals, Inc. | 262.86 Thousand USD | -10.323% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | 9.63 Million USD | 96.991% |
| Vir Biotechnology, Inc. | 111.67 Million USD | 99.74% |
| Evaxion Biotech A/S | 8.48 Million USD | 96.584% |
| Ocular Therapeutix, Inc. | 74.92 Million USD | 99.613% |
| Verve Therapeutics, Inc. | 64.71 Million USD | 99.552% |
| Tyra Biosciences, Inc. | 6.21 Million USD | 95.335% |
| Cingulate Inc. | 135.09 Thousand USD | -114.657% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 98.768% |
| Connect Biopharma Holdings Limited | 180 Thousand USD | -61.111% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Bolt Biotherapeutics, Inc. | 17.43 Million USD | 98.337% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | 936 Thousand USD | 69.017% |
| Madrigal Pharmaceuticals, Inc. | 115.48 Million USD | 99.749% |
| ImmunityBio, Inc. | 836.95 Million USD | 99.965% |
| Korro Bio, Inc. | 31.21 Million USD | 99.071% |
| Kineta, Inc. | 150 Thousand USD | -93.333% |
| BioVie Inc. | 349.89 Thousand USD | 17.118% |
| Codexis, Inc. | 12.24 Million USD | 97.631% |
| Celularity Inc. | 26.17 Million USD | 98.892% |
| Aileron Therapeutics, Inc. | 91.41 Million USD | 99.683% |
| Crinetics Pharmaceuticals, Inc. | 47.55 Million USD | 99.39% |
| Virax Biolabs Group Limited | 176.34 Thousand USD | -64.45% |
| Cibus, Inc. | 17.67 Million USD | 98.359% |
| IN8bio, Inc. | 3.37 Million USD | 91.418% |
| Adverum Biotechnologies, Inc. | 64.62 Million USD | 99.551% |
| Avalo Therapeutics, Inc. | 2 Million USD | 85.5% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.979% |
| Eyenovia, Inc. | 8.95 Million USD | 96.762% |
| Puma Biotechnology, Inc. | 65.65 Million USD | 99.558% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Elevation Oncology, Inc. | 30.13 Million USD | 99.038% |
| Xilio Therapeutics, Inc. | 8.14 Million USD | 96.438% |
| Cardiff Oncology, Inc. | 1.45 Million USD | 80.11% |
| Enanta Pharmaceuticals, Inc. | 21.23 Million USD | 98.635% |
| Regulus Therapeutics Inc. | 1.05 Million USD | 72.512% |
| Moolec Science SA | 99.04 Thousand USD | -192.793% |
| Acumen Pharmaceuticals, Inc. | 27.62 Million USD | 98.95% |
| LAVA Therapeutics N.V. | 591 Thousand USD | 50.931% |
| Atea Pharmaceuticals, Inc. | 1.64 Million USD | 82.339% |
| Compass Therapeutics, Inc. | 536 Thousand USD | 45.896% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 31.74 Thousand USD | -813.616% |
| Humacyte, Inc. | 38.6 Million USD | 99.249% |
| PMV Pharmaceuticals, Inc. | 12.43 Million USD | 97.668% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 1.86 Million USD | 84.459% |
| Trevi Therapeutics, Inc. | 1.03 Million USD | 71.899% |
| Notable Labs, Ltd. | 1.52 Million USD | 80.996% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 97.889% |
| DiaMedica Therapeutics Inc. | 317 Thousand USD | 8.517% |
| Vera Therapeutics, Inc. | 49.87 Million USD | 99.419% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | 130 Thousand USD | -123.077% |
| PepGen Inc. | 17.1 Million USD | 98.304% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.16 Million USD | 93.034% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 578 Thousand USD | 49.827% |
| XOMA Corporation | 118.51 Million USD | 99.755% |
| ARS Pharmaceuticals, Inc. | 37 Thousand USD | -683.784% |
| Bionomics Limited | 117.62 Million USD | 99.753% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 94.831% |
| uniQure N.V. | 130.06 Million USD | 99.777% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 58.59 Million USD | 99.505% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 686 Thousand USD | 57.726% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 93.313% |
| FibroBiologics, Inc. Common Stock | 1.38 Million USD | 79.061% |
| Altimmune, Inc. | 175 Thousand USD | -65.714% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 94.831% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Zevra Therapeutics, Inc. | 5.06 Million USD | 94.276% |
| Benitec Biopharma Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 99.657% |
| NKGen Biotech, Inc. Common Stock | 9.93 Million USD | 97.08% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 6.37 Million USD | 95.454% |
| NKGen Biotech, Inc. Warrants | 9.93 Million USD | 97.08% |
| argenx SE | 15.35 Million USD | 98.111% |
| Immunome, Inc. | 1.34 Million USD | 78.358% |
| Verona Pharma plc | 48.37 Million USD | 99.401% |
| enGene Holdings Inc. Warrants | 9.21 Million USD | 96.853% |
| Shattuck Labs, Inc. | 3.4 Million USD | 91.486% |
| CervoMed Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 85 Thousand USD | -241.176% |
| Dianthus Therapeutics, Inc. | 168 Thousand USD | -72.619% |
| Moolec Science SA | 99.04 Thousand USD | -192.793% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Design Therapeutics, Inc. | 2.33 Million USD | 87.575% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| Seelos Therapeutics, Inc. | - USD | -Infinity% |
| Achilles Therapeutics plc | 1.07 Million USD | 73.048% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| CG Oncology, Inc. Common stock | 13 Thousand USD | -2130.769% |
| Fractyl Health, Inc. Common Stock | 342.48 Million USD | 99.915% |
| Rani Therapeutics Holdings, Inc. | 24.48 Million USD | 98.816% |
| MoonLake Immunotherapeutics | 2.49 Million USD | 88.4% |
| Tourmaline Bio, Inc. | 194 Thousand USD | -49.485% |
| Beam Therapeutics Inc. | 159.91 Million USD | 99.819% |
| Mirum Pharmaceuticals, Inc. | 306.42 Million USD | 99.905% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| Aadi Bioscience, Inc. | 833 Thousand USD | 65.186% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | 59.82 Thousand USD | -384.771% |
| NeurAxis, Inc. | 27.07 Thousand USD | -971.257% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 71.0% |
| Lumos Pharma, Inc. | 6 Million USD | 95.167% |
| Opiant Pharmaceuticals, Inc. | 16.74 Million USD | 98.268% |
| Palisade Bio, Inc. | 90 Thousand USD | -222.222% |
| Nutriband Inc. | 79.82 Thousand USD | -263.29% |
| Taysha Gene Therapies, Inc. | 40.5 Million USD | 99.284% |
| Neurogene Inc. | 13.37 Million USD | 97.831% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 26.26 Million USD | 98.896% |
| Athira Pharma, Inc. | 1.21 Million USD | 76.171% |
| HCW Biologics Inc. | 6.3 Million USD | 95.4% |
| XOMA Corporation | 118.51 Million USD | 99.755% |
| Nektar Therapeutics | 112.62 Million USD | 99.743% |
| Arvinas, Inc. | 800 Thousand USD | 63.75% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 97.994% |
| Merus N.V. | 10.48 Million USD | 97.235% |
| Omega Therapeutics, Inc. | 14.88 Million USD | 98.052% |
| Quince Therapeutics, Inc. | 13.42 Million USD | 97.84% |
| Rezolute, Inc. | 1.66 Million USD | 82.53% |
| Clene Inc. | 7.15 Million USD | 95.945% |
| Indaptus Therapeutics, Inc. | 73.34 Thousand USD | -295.375% |
| BeyondSpring Inc. | 3.36 Million USD | 91.379% |
| Synlogic, Inc. | 12.49 Million USD | 97.678% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Werewolf Therapeutics, Inc. | 32.65 Million USD | 99.112% |
| Krystal Biotech, Inc. | 6.62 Million USD | 95.619% |
| Karyopharm Therapeutics Inc. | 170.91 Million USD | 99.83% |
| SpringWorks Therapeutics, Inc. | 5.99 Million USD | 95.163% |
| Lipella Pharmaceuticals Inc. | 47.37 Thousand USD | -512.189% |
| MannKind Corporation | 252.15 Million USD | 99.885% |
| Ikena Oncology, Inc. | 7.18 Million USD | 95.961% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 199 Thousand USD | -45.729% |
| Gossamer Bio, Inc. | 197.4 Million USD | 99.853% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 520 Thousand USD | 44.231% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 281.32 Million USD | 99.897% |
| Mural Oncology plc | 8.91 Million USD | 96.746% |
| Disc Medicine, Inc. | 1.43 Million USD | 79.805% |
| Champions Oncology, Inc. | 6.09 Million USD | 95.24% |
| REGENXBIO Inc. | 82.22 Million USD | 99.647% |
| Ensysce Biosciences, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 494 Thousand USD | 41.296% |
| Edgewise Therapeutics, Inc. | 4.43 Million USD | 93.46% |
| Vaxart, Inc. | 2.62 Million USD | 88.944% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 271.63 Thousand USD | -6.762% |
| Cellectis S.A. | 36.24 Million USD | 99.2% |
| Longeveron Inc. | 1.44 Million USD | 79.972% |
| Repare Therapeutics Inc. | 1.01 Million USD | 71.287% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.974% |
| Inozyme Pharma, Inc. | 44.76 Million USD | 99.352% |
| Revolution Medicines, Inc. | 80.57 Million USD | 99.64% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | 3.2 Million USD | 90.96% |
| ArriVent BioPharma, Inc. Common Stock | 177 Thousand USD | -63.842% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 123 Thousand USD | -135.772% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.96% |
| Denali Therapeutics Inc. | 44.98 Million USD | 99.355% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 12.5 Million USD | 97.681% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | 135.09 Thousand USD | -114.657% |
| Passage Bio, Inc. | 22.92 Million USD | 98.735% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.03 Million USD | 95.198% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 647 Thousand USD | 55.178% |
| Scinai Immunotherapeutics Ltd. | 20.16 Million USD | 98.562% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 407.45 Thousand USD | 28.827% |
| Carisma Therapeutics, Inc. | 1.18 Million USD | 75.589% |
| Unicycive Therapeutics, Inc. | 466 Thousand USD | 37.768% |
| OmniAb, Inc. | 22.07 Million USD | 98.686% |
| Anew Medical, Inc. | 1.54 Million USD | 81.169% |
| Fennec Pharmaceuticals Inc. | 29.55 Million USD | 99.019% |
| Lipocine Inc. | - USD | -Infinity% |
| Lexeo Therapeutics, Inc. Common Stock | 9.03 Million USD | 96.79% |
| Nautilus Biotechnology, Inc. | 31.09 Million USD | 99.067% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 92.847% |
| G1 Therapeutics, Inc. | 51.55 Million USD | 99.438% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | - USD | -Infinity% |
| Ocugen, Inc. | 6.36 Million USD | 95.445% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 97.947% |
| Q32 Bio Inc. | - USD | -Infinity% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | 56.845% |
| Alumis Inc. Common Stock | 30.86 Million USD | 99.06% |
| Equillium, Inc. | 384 Thousand USD | 24.479% |
| Kyverna Therapeutics, Inc. | 6.15 Million USD | 95.291% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Dominari Holdings Inc. | 3.02 Million USD | 90.423% |
| Edesa Biotech, Inc. | 19.77 Thousand USD | -1366.646% |
| vTv Therapeutics Inc. | 169 Thousand USD | -71.598% |
| Bio-Techne Corporation | 319 Million USD | 99.909% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 99.491% |
| Harmony Biosciences Holdings, Inc. | 178.56 Million USD | 99.838% |
| Prelude Therapeutics Incorporated | 15.4 Million USD | 98.118% |
| Candel Therapeutics, Inc. | 12.38 Million USD | 97.658% |
| iTeos Therapeutics, Inc. | 4.8 Million USD | 93.967% |
| Nkarta, Inc. | 82.27 Million USD | 99.648% |
| BioCardia, Inc. | 982 Thousand USD | 70.468% |
| Iterum Therapeutics plc | 18.95 Million USD | 98.47% |